{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:33:46Z","timestamp":1793745226953,"version":"4.6.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69294-3","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:14:33Z","timestamp":1773850473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study"],"prefix":"10.1038","volume":"17","author":[{"given":"Valerie","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6315-992X","authenticated-orcid":false,"given":"Apoorvaa S.","family":"Sachidanand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Onners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0072-5752","authenticated-orcid":false,"given":"Hanfei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"McPhaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Durham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Hacker-Prietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol K.","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2110-7697","authenticated-orcid":false,"given":"Dung T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"De Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-9041","authenticated-orcid":false,"given":"Michael","family":"Pishvaian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Christenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8464-9904","authenticated-orcid":false,"given":"Elizabeth D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsen","family":"Osipov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Burkhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Lafaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sugar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-6549","authenticated-orcid":false,"given":"Elizabeth M.","family":"Jaffee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-6940","authenticated-orcid":false,"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6646-0200","authenticated-orcid":false,"given":"Daniel A.","family":"Laheru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-2541","authenticated-orcid":false,"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"69294_CR1","doi-asserted-by":"crossref","unstructured":"Siegel R. L., Miller K. D. & Jemal A. Cancer statistics, 2019. CACancer J. Clin. 69,7\u201334.(2019).","DOI":"10.3322\/caac.21551"},{"key":"69294_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","volume":"270","author":"G Gemenetzis","year":"2019","unstructured":"Gemenetzis, G. et al. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Annals of surgery 270, 340\u2013347 (2019).","journal-title":"Annals of surgery"},{"key":"69294_CR3","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo, M. Pancreatic cancer. N. Engl. J. Med. 362, 1605\u20131617 (2010).","journal-title":"N. Engl. J. Med."},{"key":"69294_CR4","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1002\/cncr.30706","volume":"123","author":"J Zhong","year":"2017","unstructured":"Zhong, J. et al. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer 123, 3486\u20133493 (2017).","journal-title":"Cancer"},{"key":"69294_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/SLA.0000000000002672","volume":"268","author":"J He","year":"2018","unstructured":"He, J. et al. Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? Ann. Surg. 268, 1\u20138 (2018).","journal-title":"Ann. Surg."},{"key":"69294_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","volume":"94","author":"AT Wild","year":"2016","unstructured":"Wild, A. T. et al. Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer. Int. J. Radiat. Oncol., Biol. Phys. 94, 571\u2013579 (2016).","journal-title":"Int. J. Radiat. Oncol., Biol. Phys."},{"key":"69294_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-024-01613-x","volume":"17","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Consensus, debate, and prospective on pancreatic cancer treatments. J. Hematol. Oncol. 17, 92 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"69294_CR8","first-page":"201","volume":"12","author":"J Kleponis","year":"2015","unstructured":"Kleponis, J., Skelton, R. & Zheng, L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol. Med. 12, 201\u2013208 (2015).","journal-title":"Cancer Biol. Med."},{"key":"69294_CR9","doi-asserted-by":"publisher","first-page":"e1016700","DOI":"10.1080\/2162402X.2015.1016700","volume":"4","author":"AA Wu","year":"2015","unstructured":"Wu, A. A., Drake, V., Huang, H.-S., Chiu, S. & Zheng, L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology 4, e1016700 (2015).","journal-title":"Oncoimmunology"},{"key":"69294_CR10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ijrobp.2012.06.020","volume":"84","author":"SC Formenti","year":"2012","unstructured":"Formenti, S. C. & Demaria, S. Radiation therapy to convert the tumor into an in situ vaccine. Int. J. Radiat. Oncol. Biol. Phys. 84, 879\u2013880 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"69294_CR11","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.3389\/fimmu.2018.02030","volume":"9","author":"S Yasmin-Karim","year":"2018","unstructured":"Yasmin-Karim, S. et al. Radiation and local anti-CD40 generate an effective in situ vaccine in preclinical models of pancreatic cancer. Front. Immunol. 9, 2030 (2018).","journal-title":"Front. Immunol."},{"key":"69294_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/imt-2017-0082","volume":"10","author":"ML Aliru","year":"2018","unstructured":"Aliru, M. L. et al. Radiation therapy and immunotherapy: what is the optimal timing or sequencing? Immunotherapy 10, 299\u2013316 (2018).","journal-title":"Immunotherapy"},{"key":"69294_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.15252\/emmm.201606674","volume":"9","author":"A Azad","year":"2017","unstructured":"Azad, A. et al. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol. Med 9, 167\u2013180 (2017).","journal-title":"EMBO Mol. Med"},{"key":"69294_CR14","doi-asserted-by":"crossref","unstructured":"Fujiwara, K. et al. Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer. J. Immunother. Cancer 8, e000351 (2020).","DOI":"10.1136\/jitc-2019-000351"},{"key":"69294_CR15","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.210245","volume":"11","author":"CT Stump","year":"2021","unstructured":"Stump, C. T., Roehle, K., Manjarrez Orduno, N. & Dougan, S. K. Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer. Open Biol. 11, 210245 (2021).","journal-title":"Open Biol."},{"key":"69294_CR16","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-19-3624","volume":"26","author":"C Xie","year":"2020","unstructured":"Xie, C. et al. Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Clin. Cancer Res. 26, 2318\u20132326 (2020).","journal-title":"Clin. Cancer Res."},{"key":"69294_CR17","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","volume":"2","author":"AR Parikh","year":"2021","unstructured":"Parikh, A. R. et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat. Cancer 2, 1124\u20131135 (2021).","journal-title":"Nat. Cancer"},{"key":"69294_CR18","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1200\/JCO.21.02511","volume":"40","author":"IM Chen","year":"2022","unstructured":"Chen, I. M. et al. Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC). J. Clin. Oncol. 40, 3180\u20133189 (2022).","journal-title":"J. Clin. Oncol."},{"key":"69294_CR19","doi-asserted-by":"crossref","unstructured":"Katz, M. H. G. et al. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma. J. Immunother. Cancer 11, e007586 (2023).","DOI":"10.1136\/jitc-2023-007586"},{"key":"69294_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2024","unstructured":"Katsikis, P. D. et al. Challenges in developing personalized neoantigen cancer vaccines. Nat. Rev. Immunol. 24, 213\u2013227 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"69294_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","volume":"23","author":"N Gong","year":"2024","unstructured":"Gong, N. et al. Enhancing in situ cancer vaccines using delivery technologies. Nat. Rev. Drug Discov. 23, 607\u2013625 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"69294_CR22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ccell.2024.05.005","volume":"42","author":"P Guasp","year":"2024","unstructured":"Guasp, P. et al. RNA vaccines for cancer: principles to practice. Cancer Cell 42, 1163\u20131184 (2024).","journal-title":"Cancer Cell"},{"key":"69294_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217390","volume":"611","author":"Y Xie","year":"2024","unstructured":"Xie, Y. et al. Cancer vaccines in focus: the next frontier in immuno-oncology. Cancer Lett. 611, 217390 (2024).","journal-title":"Cancer Lett."},{"key":"69294_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"69294_CR25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.trecan.2024.06.003","volume":"10","author":"A Brandenburg","year":"2024","unstructured":"Brandenburg, A. et al. Next-generation cancer vaccines and emerging immunotherapy combinations. Trends Cancer 10, 749\u2013769 (2024).","journal-title":"Trends Cancer"},{"key":"69294_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","volume":"2","author":"ER Lutz","year":"2014","unstructured":"Lutz, E. R. et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol. Res 2, 616\u2013631 (2014).","journal-title":"Cancer Immunol. Res"},{"key":"69294_CR27","doi-asserted-by":"crossref","unstructured":"Li, K. et al. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell 40, 1374\u20131391.e7 (2022).","DOI":"10.1016\/j.ccell.2022.10.001"},{"key":"69294_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39196-9","volume":"14","author":"T Heumann","year":"2023","unstructured":"Heumann, T. et al. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nat. Commun. 14, 3650 (2023).","journal-title":"Nat. Commun."},{"key":"69294_CR29","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2021.39.15_suppl.4134","volume":"39","author":"V Lee","year":"2021","unstructured":"Lee, V. et al. A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC). J. Clin. Oncol. 39, 4134\u20134134 (2021).","journal-title":"J. Clin. Oncol."},{"key":"69294_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk1827","volume":"10","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Sci. Adv. 10, eadk1827 (2024).","journal-title":"Sci. Adv."},{"key":"69294_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","volume":"155","author":"MA Teriaca","year":"2021","unstructured":"Teriaca, M. A. et al. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome. Radiother. Oncol. 155, 232\u2013236 (2021).","journal-title":"Radiother. Oncol."},{"key":"69294_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109541","volume":"183","author":"FR van \u2018t Land","year":"2023","unstructured":"van \u2018t Land, F. R. et al. Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed Mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX-the LAPC-2 trial. Radiother. Oncol. 183, 109541 (2023).","journal-title":"Radiother. Oncol."},{"key":"69294_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.prro.2022.02.009","volume":"12","author":"CS Hill","year":"2022","unstructured":"Hill, C. S. et al. Multiagent chemotherapy and stereotactic body radiation therapy in patients with unresectable pancreatic adenocarcinoma: a prospective nonrandomized controlled trial. Pract. Radiat. Oncol. 12, 511\u2013523 (2022).","journal-title":"Pract. Radiat. Oncol."},{"key":"69294_CR34","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/cncr.29161","volume":"121","author":"JM Herman","year":"2015","unstructured":"Herman, J. M. et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 121, 1128\u20131137 (2015).","journal-title":"Cancer"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69294-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69294-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69294-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T15:07:25Z","timestamp":1778425645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69294-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69294"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69294-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.Z. receives grant support from Bristol-Meyer Squibb, Merck, AstraZeneca, iTeos, Amgen, NovaRock, Inxmed, Halozyme, and Abmeta. L.Z. is a paid consultant\/Advisory Board member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia\/Xilio, QED, Natera, Novagenesis, Snow Lake Capitals, BioArdis, Tempus, Amberstone, Pfizer, Tavotek, and Mingruizhiyao. L.Z. holds shares at Alphamab, Amberstone, and Mingruizhiyao. E.M.J. receives grant support from the Lustgarten Foundation, Bristol-Meyers Squibb, Genentech, and AstraZeneca; is a paid consultant for NextCure, Genocea, DragonFly, Stimit, CSTONE, Achilles, and Candel; is on the advisory board of Parker Institute and Break Through Cancer; is a founder of Abmeta Biotech; and is the Chief Medical Advisor for the Lustgarten Foundation. J.M.H consults and holds equity from Histosonics, consults for BTG, and receives research support to the Northwell Health System from Canopy Cancer Collective\/1440 Foundation. R.A.A. serves on the advisory board of RAPT Therapeutics, AstraZeneca, Merck SD, Bristol-Myers Squibb, and receives research funding from RAPT Therapeutics, Bristol-Myers Squibb and the National Institute of Health. There is no relevant conflict of interest disclosed by all other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4141"}}